Fluoxetine hapten, monoclonal antibody, hybridoma cell line and application
By preparing fluoxetine artificial antigen and complete antigen, hybridoma cell lines with high specific monoclonal antibodies were screened, which solved the problems of high cost and insufficient sensitivity of fluoxetine detection in the prior art, and achieved rapid, simple and cost-effective Intact fluoxetine detection method is suitable for the testing of drugs and weight loss products.
Patent Information
- Application Number
- CN202310068430.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-02-06
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2043-02-06
AI Technical Summary
The detection methods of fluoxetine in the prior art are costly, have high requirements for the environment and technicians, and lack of monoclonal antibodies with high specificity and high sensitivity, limiting the rapid and accurate detection of fluoxetine.
By preparing fluoxetine artificial antigen and complete antigen, hybridoma cell lines secreting highly specific monoclonal antibodies were screened for development of simple and efficient fluoxetine immunoassay methods, including colloidal gold immunochromatography test strips and ELISA Reagent test kit.
It has achieved rapid, simple, cheap, sensitive and specific detection of fluoxetine, and provided a new method for detecting fluoxetine content in medicines and weight loss products, which has practical application value.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure HDA0004062904400000011
Abstract
Description
Technical Field
[0001] The invention belongs to the field of food safety immunoassay, and specifically relates to fluoxetine hapten, monoclonal antibody, hybridoma cell line and application. Background Art
[0002] Fluoxetine is the first 5-HT reuptake inhibitor antidepressant to be marketed. It acts on the central nervous system. In addition to being commonly used to treat depression, fluoxetine can also treat obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder (PTSD), etc. It has a definite effect, mild side effects, and the market is developing rapidly. Because it can selectively inhibit the passage of 5-hydroxytryptamine transporters and block the reuptake of 5-hydroxytryptamine by the presynaptic membrane, it can treat depression while also having the effect of treating bulimia nervosa. Therefore, consuming fluoxetine can suppress appetite. The 2017 version of the consensus guidelines for monitoring psychiatric therapeutic drugs of the Association of Neuropsychopharmacology and Pharmacopsychiatry (AGNP) recommends that the minimum mass concentration of fluoxetine has a therapeutic window of 60 ng / mL and the total mass concentration has a therapeutic window of 120-500 ng / mL. Therefore, it is of great significance to detect fluoxetine in drugs and weight loss products and establish a detection method for fluoxetine.
[0003] In the current related technologies, the detection of fluoxetine is mainly based on instrumental analysis. Although this method has high accuracy and sensitivity, its high cost and high requirements for the detection environment and technicians have limited its development. With the rapid development of immunoassay technology in recent years, it has become possible to establish an efficient and rapid immunoassay method for fluoxetine, including enzyme-linked immunosorbent assay (ELISA), colloidal gold immunochromatography test strip technology and immunomagnetic bead technology. An important prerequisite for the establishment of these methods is to screen out highly specific monoclonal monomers for fluoxetine, among which the synthesis of artificial antigens is an important step; after immunizing mice with the obtained complete antigen, how to screen for positive mice with better inhibition, and how to fuse mouse spleen cells and tumor cells to obtain hybridoma cell lines, further research is needed; how to make fluoxetine monoclonal antibodies have strong specificity and high sensitivity also requires further research. Summary of the invention
[0004] In order to solve the problems existing in the related technologies, the present invention provides a method for preparing an artificial fluoxetine antigen. The preparation process is more concise and efficient, and provides necessary artificial antigens for future research. A hybridoma cell strain that secretes fluoxetine monoclonal antibodies is also provided, and is applied to the research of fluoxetine immunoassay methods. The monoclonal antibodies prepared by the hybridoma cell strain have good specificity and detection sensitivity to fluoxetine, and can be used to establish an immunological detection method for fluoxetine, or to establish a colloidal gold immunochromatographic test strip rapid detection method, laying a foundation for the research, development and promotion of indirect competitive ELISA kits and colloidal gold test strips.
[0005] The present invention provides a method for preparing a fluoxetine hapten. The method comprises the following steps: fluoxetine is reacted with ethyl 4-bromobutyrate to obtain a hapten intermediate; the hapten intermediate is hydrolyzed under alkaline conditions, the pH is adjusted to acidic, a precipitate is obtained, and the fluoxetine hapten FXT-H is obtained by centrifugal drying. The reaction formula is as follows:
[0006]
[0007] Fluoxetine is reacted with ethyl 4-bromobutyrate to add a connecting arm to the original structure, so that the overall structure can expose the carboxyl group of the product, namely the hapten FXT-H.
[0008] According to the present invention, a fluoxetine complete antigen is provided, which is obtained by coupling the fluoxetine hapten with a carrier protein, that is, the hapten FXT-H is coupled with the carrier protein by the carbodiimide method to obtain the fluoxetine artificial antigen.
[0009] According to the present invention, a fluoxetine monoclonal antibody can be obtained by immunizing mice with the fluoxetine complete antigen.
[0010] The present invention also provides a hybridoma cell strain secreting the fluoxetine monoclonal antibody, which is obtained by immunizing mice and cell fusion. The hybridoma cell strain has been deposited in the General Microbiology Center of China National Microbiological Culture Collection Committee on March 3, 2022, with the deposit name of monoclonal cell strain YMZ, the deposit number of CGMCC No. 45124, and the deposit address of No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.
[0011] According to the present invention, the fluoxetine artificial antigen is used to detect the fluoxetine content in the analysis sample, and is used to prepare a fluoxetine immunoassay kit, or is used to prepare a colloidal gold test strip for fluoxetine detection.
[0012] According to the present invention, the fluoxetine complete antigen is used to detect the fluoxetine content in an analysis sample, to prepare a fluoxetine immunoassay kit, or to prepare a colloidal gold test strip for fluoxetine detection.
[0013] According to the present invention, a kit or a colloidal gold test strip is provided, comprising the fluoxetine monoclonal antibody.
[0014] According to the present invention, the kit or colloidal gold test strip is used to detect and analyze the content of fluoxetine in medicines and weight loss products.
[0015] The basic steps for preparing the hybridoma cell line secreting fluoxetine monoclonal antibodies provided by the present invention are:
[0016] (1) Preparation and identification of complete antigen: The synthesized hapten FXT-H is connected to the amino group of a protein carrier. After the reaction is completed, the complete antigen and the uncoupled small molecule hapten are separated by dialysis. The complete antigen is identified by ultraviolet absorption scanning to obtain the complete antigen;
[0017] (2) Immunization of mice: BALB / c mice aged 6 to 8 weeks were selected for immunization. After the complete antigen (FXT-H-BSA) and Freund's adjuvant were completely emulsified, the mice were immunized by multiple subcutaneous injections (except for sprint immunization). Freund's complete adjuvant was used for the first immunization, and Freund's incomplete adjuvant was used for multiple booster immunizations, with the dose halved. No adjuvant was used for sprint immunization, and it was directly diluted with normal saline and injected intraperitoneally. The immunization dose for sprint immunization was half of the dose for multiple booster immunizations. There was a one-month interval between the first immunization and the second booster immunization, a 21-day interval between multiple booster immunizations, and an 18-21-day interval between the sprint immunization and the last booster immunization. After the three immunizations, blood was collected from the tail on the 7th day of each booster immunization, and the immune effect of the mice was detected by indirect competitive enzyme-linked immunosorbent assay (ic-ELISA), where the coated complete antigen was FXT-H-OVA.
[0018] (3) Cell fusion and cell line establishment: Mouse spleen cells and mouse myeloma cells were fused by the polyethylene glycol (PEG 4000) method and cultured in a selective medium (HAT medium). After one week of fusion, the positive cell wells were detected by indirect ELISA, and the inhibitory effect of the positive cell wells was further determined by indirect competitive ELISA. The positive cell wells with better inhibition were subcloned three times by the limiting dilution method, and finally a hybridoma cell line secreting monoclonal antibodies against fluoxetine was obtained by screening;
[0019] (4) Identification of hybridoma cell line properties: mouse monoclonal antibody Ig class / subclass identification was determined using an enzyme-labeled secondary antibody kit; IC was determined by ELISA 50 Value, cross-reaction rate.
[0020] Compared with the related art, the present invention has at least the following beneficial effects:
[0021] The monoclonal antibody secreted by the hybridoma cell line provided by the present invention has good detection sensitivity and affinity for fluoxetine in medicines and weight loss products, and can realize the detection of fluoxetine content. IC 50 The value is 1ng / mL, which provides a new means for establishing a rapid, simple, inexpensive, sensitive and specific detection method for fluoxetine and has practical application value.
[0022] Biomaterial Deposit
[0023] A hybridoma cell line secreting fluoxetine monoclonal antibody is classified and named: Monoclonal cell line YMZ. The preservation unit is: General Microbiology Center of China Microbiological Culture Collection Administration. The preservation address is: No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing. The preservation number is: CGMCC No.45124, and the preservation date is: March 3, 2022. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] The accompanying drawings are used to provide a further understanding of the present invention and constitute a part of the specification. Together with the following specific embodiments, they are used to explain the present invention but do not constitute a limitation of the present invention. In the accompanying drawings:
[0025] Figure 1 is the standard inhibition curve of monoclonal antibody against fluoxetine; DETAILED DESCRIPTION
[0026] The following examples of the present invention are only used as further explanations of the present invention and cannot be used as limiting contents or scopes of the present invention. The present invention is further explained by examples.
[0027] The culture medium involved in the following examples is as follows:
[0028] RPMI-1640 medium (mg / L): L-arginine 290, L-asparagine 50, L-aspartic acid 20, L-cystine dihydrochloride 65.15, L-glutamic acid 20, glycine 10, L-histidine 15, L-hydroxyproline 20, L-isoleucine 50, L-leucine 50, L-lysine hydrochloride 40, L-methionine 15, L-phenylalanine 15, L-proline 20, L-serine 30, L-threonine 20, L-tryptophan 5, L-tyrosine 23.19, L-valine 20, p-aminobenzoic acid 1, calcium nitrate 100, anhydrous magnesium sulfate 48.84, anhydrous sodium dihydrogen phosphate 676.13, potassium chloride 400, sodium chloride 6000, glucose 2000, reduced glutathione 1, phenol red 5, L-glutamine 300, biotin 0.2, D-calcium pantothenate 0.25, folic acid 1, i-inositol 35, niacinamide 1, choline chloride 3, pyridoxine hydrochloride 1, riboflavin 0.2, thiamine hydrochloride 1, vitamin B12 0.005, sodium bicarbonate 2000.
[0029] The reagents involved in the following examples are as follows:
[0030] Carbonate buffer (CBS): Weigh 1.59 g of Na2CO3 and 2.93 g of NaHCO3, dissolve them in a small amount of double distilled water respectively and mix them, add double distilled water to about 800 mL and mix well, adjust the pH to 9.6, add double distilled water to 1000 mL, and store at 4°C for later use.
[0031] Phosphate buffered saline (PBS): 8.00 g NaCl, 0.2 g KCl, 0.2 g KH2PO4, 2.9 g Na2HPO4·12H2O, dissolved in 800 mL pure water, adjusted to pH 7.2-7.4 with NaOH or HCl, and made up to 1000 mL;
[0032] PBST: PBS containing 0.05% Tween 20;
[0033] TMB colorimetric solution: Solution A: 18.43g Na2HPO4.12H2O, 9.33g citric acid, dilute to 1000mL with pure water; Solution B: 60mg TMB dissolved in 100mL ethylene glycol. Mix solution A and solution B in a ratio of 5:1 to obtain the TMB colorimetric solution, which can be mixed before use.
[0034] The detection methods involved in the following embodiments are as follows:
[0035] Fluoxetine inhibition rate detection method: The most suitable antigen and antibody concentrations in ic-ELISA were selected by chessboard test. The antigen was diluted to 0.01, 0.03, 0.1 and 0.3 μg / mL with carbonate buffer (CBS), and the antibody was diluted to 0.01, 0.03, 0.1 and 0.3 μg / mL with antibody diluent. After selecting the optimal working point, the standard gradient of fluoxetine was diluted with phosphate buffer solution (PBS (K + )) was diluted to 0, 0, 0.14, 0.41, 1.23, 3.70, 11.11, 33.33, and 100 ng / mL. The ic-ELISA procedure was followed and the graph was drawn using OriginPro 8.5 (the results are shown in Figure 1 The standard inhibition curve was obtained and the IC 50 .
[0036] The invention immunizes mice with fluoxetine complete antigen, performs cell fusion, HAT selective medium culture, and performs cell screening by limiting dilution method and ic-ELISA, and finally obtains a hybridoma cell strain capable of secreting highly specific antibodies against fluoxetine.
[0037] Example 1 Preparation and identification of artificial antigens:
[0038] 1.1 Derivation of artificial hapten FXT-H:
[0039] First, a connecting arm is added to the original structure of fluoxetine and ethyl 4-bromobutyrate, and then alkaline hydrolysis, separation and purification are performed to prepare the fluoxetine artificial hapten. The synthetic route is as follows (I):
[0040]
[0041] Weigh 618 mg (2.0 mmol) of fluoxetine and dissolve it in 3 mL of acetonitrile. Add 424 mg (4.0 mmol) of sodium carbonate and 572 μL (4.0 mmol) of ethyl 4-bromobutyrate. Reflux at 100°C with stirring for 24 h. When the reaction is over, add 50 μL of ice-pure water to stop the reaction. The reaction solution is evaporated under reduced pressure to near dryness. The substrate is blown dry with nitrogen to obtain the hapten intermediate.
[0042] The above hapten intermediate was dissolved in 5 mL of 20 v / v% methanol / NaOH (1M) solution and refluxed and stirred at 80°C for 2 h. After the reaction, the reaction solution was adjusted to pH 3 with 1M HCl solution. A flocculent precipitate appeared and was centrifuged at 8000 r / min for 10 minutes. The precipitate was dried in a 37°C oven to obtain the fluoxetine hapten FXT-H, which was stored at 4°C for future use.
[0043] 1.2 Preparation and identification of complete fluoxetine antigen:
[0044] Weigh 1.78 mg of fluoxetine hapten FXT-H, 1.55 mg of N-hydroxysuccinimide, and 2.58 mg of 1-ethylcarbodiimide hydrochloride, dissolve in 300 μL of N,N-dimethylformamide (DMF) to obtain solution A, and stir at room temperature for 4-6 hours. Weigh 10.0 mg of BSA (FXT-H to BSA molar ratio is 30:1) and dissolve in 2 mL of carbonate buffer solution to obtain solution B. While stirring at room temperature, add solution A dropwise to solution B, adjust the pH of the mixture to 8-9 with 1 M NaOH solution, and stir at room temperature for overnight reaction to obtain the conjugate FXT-H-EDC-BSA. In addition, the conjugate FXT-H-EDC-OVA method is similar to the above method.
[0045] Finally, the solution was dialyzed against 0.01 M phosphate buffer solution (PBS, pH=7.4) to remove small molecules that did not participate in the reaction and obtain the complete antigen FXT-H-EDC-BSA / OVA, which was used as an immunogen.
[0046] Example 2: Preparation of hybridoma cell lines secreting fluoxetine monoclonal antibodies
[0047] 2.1 Acquisition of animal immunity
[0048] Healthy 6-8 week old BALB / c mice were selected for immunization. After the complete antigen FXT-H-EDC-BSA was mixed and emulsified with an equal amount of Freund's adjuvant, the BALB / c mice were immunized by multiple subcutaneous injections on the back of the neck (except for sprint immunization). Complete Freund's adjuvant was used for the first immunization, with a dose of 100ug / mouse; incomplete Freund's adjuvant was used for multiple booster immunizations and the dose was halved to 50ug / mouse; no adjuvant was used for sprint immunization, and it was directly diluted with normal saline and injected intraperitoneally, and the dose was halved again to 25ug / mouse. There was an interval of one month between the first immunization and the second booster immunization, 21 days between multiple booster immunizations, and 18-21 days between the sprint immunization and the last booster immunization. The indirect competitive enzyme-linked immunosorbent assay (ic-ELISA) was used to detect the immune effect of mice, that is, to detect the titer and inhibition of mouse serum, and select mice with high titer and IC 50 Low-dose mouse cells were fused.
[0049] 2.2 Cell fusion and screening
[0050] Three days after the shock immunization, cell fusion was performed according to the conventional PEG (polyethylene glycol, molecular weight 4000) method. The specific steps are as follows:
[0051] a. Remove the eyeballs of mice to collect blood. After killing the mice by cervical dislocation, immediately immerse them in 75% alcohol for about 5 minutes for disinfection. Remove the spleen of the mice by aseptic operation, grind them moderately with the rubber tip of a syringe and pass them through a 200-mesh cell sieve to obtain a spleen cell suspension, collect them, and centrifuge them (1200r / min, 10min). Wash the spleen cells three times with RPMI-1640 medium. After the last centrifugation, dilute the spleen cells to a certain volume, count them, and set aside;
[0052] b. Collect SP2 / 0 cells: 7-10 days before fusion, SP2 / 0 tumor cells were cultured in RPMI-1640 medium containing 10% FBS (fetal bovine serum) in a 5% CO2 incubator. Before fusion, the number of SP2 / 0 tumor cells should reach 1-4×10 7 , to ensure that SP2 / 0 tumor cells are in the logarithmic growth phase before fusion. When fusion occurs, tumor cells are collected, suspended in RPMI-1640 basal culture medium, and cell counts are performed;
[0053] c. The fusion process lasts for 7 minutes. In the first minute, 1 mL of PEG 1500 was added to the cells from slow to fast speed; in the second minute, the cells were allowed to stand. In the third and fourth minutes, 1 mL of RPMI-1640 medium was added within 1 minute; in the fifth and sixth minutes, 2 mL of RPMI-1640 medium was added within 1 minute; in the seventh minute, 1 mL of RPMI-1640 medium was added every 10 seconds. Then, the cells were incubated at 37°C for 5 minutes. Centrifuged (800 rpm, 10 minutes), the supernatant was discarded, and the cells were resuspended in RPMI-1640 screening culture medium containing 20% fetal bovine serum and 2% 50×HAT, and added to a 96-well cell plate at 200 μL / well, and cultured in a 37°C, 5% CO2 incubator.
[0054] 2.3 Cell screening and cell line establishment
[0055] On the third day after cell fusion, the fused cells were half-changed with HAT medium; on the fifth day, the medium was fully changed with RPMI-1640 transition medium (HT medium) containing 20% fetal bovine serum and 1% 100×HT; on the seventh day, the cell supernatant was taken for screening. The screening was divided into two steps: the first step was to use FXT-H-EDC-OVA as the coating antigen, and the positive cell wells were screened by ic-ELISA method; the second step was to use fluoxetine as the standard, and the inhibitory effect of positive cells was determined by ic-ELISA method.
[0056] The cell wells with good inhibition of fluoxetine standard were selected and subcloned by limiting dilution method, and tested by the same method seven days later. Subcloning was performed three times according to the above method, and finally a hybridoma cell line secreting fluoxetine-specific monoclonal antibody was obtained.
[0057] Example 3: Preparation of fluoxetine monoclonal antibody
[0058] 8-10 week old BALB / c mice were selected and each mouse was intraperitoneally injected with 1 mL of sterile paraffin oil. Seven days later, each mouse was intraperitoneally injected with 2×10 6 Hybridoma cells, ascites was collected from the 7th day, and the ascites was purified by the caprylic acid-saturated ammonium sulfate method: under slightly acidic conditions, caprylic acid can precipitate other impurities except IgG immunoglobulin in the ascites, and then centrifuge and discard the precipitate; then use an equal amount of saturated ammonium sulfate solution to precipitate IgG type monoclonal antibodies, centrifuge, discard the supernatant, dissolve with 0.01M PBS solution (pH7.4), dialyze for desalination, and finally obtain the purified monoclonal antibody and store it at -20°C.
[0059] Example 4: Identification of Fluoxetine Monoclonal Antibodies
[0060] 4.1 Coating: Dilute the original FXT-H-EDC-OVA to the optimal working concentration of 0.1 μg / mL with 0.05M carbonate buffer (pH=9.6), and add it to the microwells of the ELISA plate, 100 μL / well, and react at 37℃ for 2 hours.
[0061] 4.2 Washing: Pour off the solution in the plate and wash with PBST washing solution 3 times, 200 μL per well each time, pat dry for 3 minutes each time;
[0062] 4.3 Blocking: Block with CBS containing 0.2% gelatin, 200 μL per well, react at 37°C for 2 hours. Wash the plate three times with PBST solution, 200 μL per well each time, 3 minutes each time, and pat dry;
[0063] 4.4 Sample addition: Use phosphate buffered saline (PBS (K + )) The standard of fluoxetine was diluted to the following levels: 0, 0.14, 0.41, 1.23, 3.70, 11.11, 33.33, 100 ng / mL and added to the blocked microwells of the ELISA plate (50 μL / well), and then the antibody was diluted to the optimal working concentration of 0.03 μg / mL and added to the microwells of the ELISA plate (50 μL / well), and each sample was repeated in 3 parallel wells, reacted at 37°C for 30 min, and the plate was washed and patted dry; 1:3000 diluted HRP-labeled horseradish peroxidase-labeled goat anti-mouse IgG (goat anti-mouse IgG secondary antibody) was added, 100 μL / well, reacted at 37°C for 30 min, and the plate was washed and patted dry;
[0064] 4.5 Color development: Add 100 μL of TMB color development solution to each well and react at 37°C in the dark for 15 minutes;
[0065] 4.6 Termination and determination: Add 50 μL of 2M H2SO4 stop solution to each well to terminate the reaction, and then use a microplate reader to measure the OD of each well. 450 The standard inhibition curve was obtained by plotting with OriginPro 8.5 and the IC 50 The standard inhibition curve of fluoxetine is as follows Figure 1 shown.
[0066] Example 5 Specificity Experiment
[0067] The IC of monoclonal antibodies against fluoxetine was determined using an indirect competitive ELISA method. 50 1 ng / mL, and its IC values for sibutramine, amphetamine, fenfluramine, olanzapine, and voroxamine were verified. 50 And cross-reaction rate:
[0068] Cross-reactivity rate = (IC 50 / IC of other compounds50 )×100%, as shown in Table 1:
[0069] Table 1 IC of anti-fluoxetine monoclonal antibodies to fluoxetine and cross-polymers 50 and cross-reaction rate
[0070] Compound <![CDATA[IC 50 (ng / mL)]]> Cross-reaction rate Fluoxetine 1 100% Norfluoxetine 1 100% Sibutramine >100 <1% Amphetamine >100 <1% Fenfluramine >100 <1% Olanzapine >100 <1% Vofloxamine >100 <1%
[0071] Cross-reactions: norfluoxetine, sibutramine, amphetamine, fenfluramine, olanzapine, voroxamine.
[0072] The cross-reaction rate of the monoclonal antibody to fluoxetine is 100%, and the cross-reaction rates to the same matrix type compounds of sibutramine, amphetamine, fenfluramine, olanzapine, and voroxamine are all less than 1%, indicating that the monoclonal antibody obtained by the present invention has a high sensitivity to fluoxetine; IC 50 The value is 1 ng / mL, indicating that the monoclonal antibody has high sensitivity and specificity. Among them, the same matrix type compound can be understood as a compound present in the same type of matrix, for example, fluoxetine, sibutramine, amphetamine, fenfluramine, olanzapine or voroxamine present in weight loss products, drugs, etc.
[0073] In addition, it should be noted that norfluoxetine is an active N-desmethyl metabolite of fluoxetine, and fluoxetine is metabolized to norfluoxetine by cytochrome P450 (CYP) 2D6, CYP2C19 and CYP3A4. The cross-reactivity rate of the monoclonal antibody provided by the present invention to norfluoxetine is 100%, and the IC 50 The value was 1 ng / mL, indicating that the monoclonal antibody can also be used to detect the content of norfluoxetine in the blood.
[0074] Example 6: Fluoxetine Immunoassay Kit
[0075] This embodiment provides a fluoxetine immunoassay kit, which comprises the fluoxetine monoclonal antibody prepared in Example 3, an ELISA plate, a fluoxetine coating antigen, a fluoxetine standard solution, a goat anti-mouse IgG secondary antibody and a TMB colorimetric solution.
[0076] The principle of the fluoxetine immunoassay kit for detecting fluoxetine is: the indirect competitive ELISA method is used to detect the content of fluoxetine in the sample to be tested. Fluoxetine-coated antigens are pre-coated in the microwells of the ELISA plate, and fluoxetine standard solution or the sample to be tested, fluoxetine monoclonal antibody, goat anti-mouse IgG secondary antibody and TMB colorimetric solution are added to prepare a fluoxetine standard inhibition curve. According to the fluoxetine standard inhibition curve and the absorbance value of the sample to be tested, the fluoxetine content in the sample to be tested is determined. The detection of fluoxetine can be achieved by operating with the commonly used methods in the field.
[0077] Example 7: Fluoxetine Detection Colloidal Gold Test Strip
[0078] This embodiment provides a colloidal gold test strip, which includes a sample pad, a colloidal gold binding pad, a nitrocellulose membrane and a water absorbent pad, wherein the nitrocellulose membrane is provided with a detection line and a quality control line in sequence, and the colloidal gold binding pad is coated with the fluoxetine monoclonal antibody prepared in Example 3. The detection line is obtained by printing the fluoxetine coated antigen. The quality control line is obtained by printing the goat anti-mouse IgG secondary antibody. The colloidal gold test strip can be assembled in a manner commonly used in the art.
[0079] Fluoxetine detection The principle of the colloidal gold test strip for detecting fluoxetine is: using the principle of indirect competition to detect whether the sample to be tested contains fluoxetine. If the sample to be tested does not contain fluoxetine, the test line does not show color, and the quality control line shows color. If the sample to be tested contains fluoxetine, both the test line and the quality control line show color. The detection of fluoxetine can be achieved by operating using the common methods in the field.
[0080] The above only introduces the technical solution of the present invention with preferred embodiments. However, for those skilled in the art, according to the ideas of the embodiments of the present invention, changes should be made in the specific implementation methods and the scope of application. Therefore, in summary, the content of this specification should not be understood as a limitation of the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of the claims of the present invention.
Claims
1. A hybridoma cell line secreting fluoxetine monoclonal antibody, characterized in that: It was deposited in the General Microbiology Center of China Culture Collection Administration on March 3, 2022. The deposit name is monoclonal cell line YMZ, the deposit number is CGMCC No.45124, and the deposit address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.
2. The hybridoma cell line secreting fluoxetine monoclonal antibody according to claim 1, characterized in that: The fluoxetine monoclonal antibody is obtained by immunizing mice with fluoxetine complete antigen.
3. The hybridoma cell line secreting fluoxetine monoclonal antibody according to claim 2, characterized in that: The fluoxetine complete antigen is obtained by coupling the fluoxetine hapten with a carrier protein.
4. The hybridoma cell line secreting fluoxetine monoclonal antibody according to claim 3, characterized in that: The preparation method of the fluoxetine hapten is as follows: fluoxetine is reacted with ethyl 4-bromobutyrate to obtain a hapten intermediate; the hapten intermediate is hydrolyzed under alkaline conditions, the pH is adjusted to acidic to obtain a precipitate, and the fluoxetine hapten is obtained by centrifugal drying. The reaction formula is as follows: 。 5. A fluoxetine monoclonal antibody, characterized in that: The protein is secreted by the hybridoma cell line according to any one of claims 1 to 4.
6. Use of the fluoxetine monoclonal antibody according to claim 5 in detecting and analyzing the content of fluoxetine, which is used to detect and analyze the content of fluoxetine in medicines and weight loss products; Or, use in preparing a fluoxetine immunoassay kit; Or, application in the preparation of colloidal gold test strips for fluoxetine detection.
7. A kit, characterized in that: Contains the fluoxetine monoclonal antibody according to claim 5.
8. A colloidal gold test strip, characterized in that: Contains the fluoxetine monoclonal antibody according to claim 5.
9. The test kit according to claim 7 or the colloidal gold test paper according to claim 8 is used for detecting and analyzing the content of fluoxetine in medicines and weight loss products.
Citation Information
Patent Citations
Preparing method of fluoxetine artificial antigen
CN108264551A
